PCM
ATRS

Prelude Capital Management’s Antares Pharma, Inc. ATRS Stock Holding History

Prelude Capital Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-47,800
Closed -$194K – 2006
2013
Q3 		$194K Buy
+47,800
New +$209K 0.03% 553

Other funds holding ATRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
MWP
MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return

Prelude Capital Management's ATRS Position: Q3 2019 in Review

Prelude Capital Management sold out of Antares Pharma, Inc. (ATRS) in Q3 2019, closing a stake of 44,560 shares — an estimated $147K sold.

Prelude Capital Management first reported a position in ATRS in Q1 2017 and held it in 5 quarters. The position peaked at $323K in Q2 2017. 135 funds tracked by Wall St. Rank hold ATRS as of Q3 2019.

  • Prelude Capital Management reported no remaining Antares Pharma, Inc. position as of Q3 2019 after selling out during the quarter.
  • Prelude Capital Management sold 44,560 Antares Pharma, Inc. shares in Q3 2019, an estimated $147K.
  • Prelude Capital Management first reported a position in Antares Pharma, Inc. in Q1 2017 and held it in 5 quarters.
  • Prelude Capital Management's Antares Pharma, Inc. position peaked at $323K in Q2 2017.
  • 135 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2019.

Based on Prelude Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.